Dr. Nathalie Franchimont is Chief Medical Officer of Beeline Medicines and brings more than 20 years of leadership experience in drug development across biotechnology and large pharmaceutical organizations. A physician-scientist by training, she has led programs spanning discovery research through early- and late-stage clinical development, global regulatory filings, and medical affairs across multiple therapeutic areas and modalities. Most recently, she served as Chief Medical Officer of Nimbus Therapeutics. Prior to Nimbus, Dr. Franchimont spent a decade at Biogen, where she last served as Senior Vice President and Head of the Multiple Sclerosis and Immunology Development Unit and held several other leadership roles across the research and development organization.
Earlier in her career, Dr. Franchimont held clinical development and medical affairs roles at Amgen. She currently serves on the Board of Directors of OMass Therapeutics.
Dr. Franchimont trained as a rheumatologist and received her M.D., Ph.D. from the University of Liège, Belgium and has conducted research at St. Francis Hospital/University of Connecticut School of Medicine, Yale University School of Medicine, and the University of Liège where she was also Chief of Clinic in Rheumatology.
